UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies

Archives of Virology

Volumn 156, Issue 12, 2011, Pages 2145-2155

  Jiang, Xiao Jing ^a,d   Sampaio, Kerstin Laib ^a   Ettischer, Nicole ^a   Stierhof, York Dieter ^b   Jahn, Gerhard ^a   Kropff, Barbara ^c   Mach, Michael ^c   Sinzger, Christian ^e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^e UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B, SIMPLEXVIRUS; GLYCOPROTEIN H, CYTOMEGALOVIRUS; GLYCOPROTEIN O, CYTOMEGALOVIRUS; MEMBRANE PROTEIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CELL CULTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; GENE DELETION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENICITY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; UMBILICAL VEIN ENDOTHELIAL CELL; VIROLOGY; VIRULENCE; VIRUS GENE;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; CELLS, CULTURED; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FIBROBLASTS; GENES, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE DELETION; VIRAL ENVELOPE PROTEINS; VIRULENCE;

HUMAN HERPESVIRUS 5;

EID: 82455209432     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-011-1105-x     Document Type: Article

References (41)

1. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U (2006) Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87: 2451-2460.
2. Akahori Y, Suzuki K, Daikoku T, Iwai M, Yoshida Y, Asano Y, Kurosawa Y, Shiraki K (2009) Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H. J Virol 83: 2020-2024.
3. Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989) A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J Gen Virol 70(Pt 4): 979-985.
4. Borza CM, Hutt-Fletcher LM (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8: 594-599.
5. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 86: 3598-3603.
6. Britt WJ (1984) Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135: 369-378.
7. Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, Barrell B, Hart H, Bell SE, Minson AC et al (1986) Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5: 3057-3063.
8. Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26: 5760-5766.
9. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78: 10023-10033.
10. Huber MT, Compton T (1998) The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 72: 8191-8197.
11. Jiang XJ, Adler B, Sampaio KL, Digel M, Jahn G, Ettischer N, Stierhof YD, Scrivano L, Koszinowski U, Mach M, Sinzger C (2008) UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J Virol 82: 2802-2812.
12. Kinzler ER, Compton T (2005) Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 79: 7827-7837.
13. Lipson SM, Shepp DH, Match ME, Axelrod FB, Whitbread JA (2001) Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 116: 52-55.
14. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84: 1005-1013.
15. Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987) Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol 68(Pt 5): 1457-1461.
16. Paterson DA, Dyer AP, Milne RS, Sevilla-Reyes E, Gompels UA (2002) A role for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable locus. Virology 293: 281-294.
17. Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A (2007) Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry in endothelial cells. J Virol 81: 11479-11488.
18. Qadri I, Navarro D, Paz P, Pereira L (1992) Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73(Pt 11): 2913-2921.
19. Ryckman BJ, Chase MC, Johnson DC (2010) Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 84: 2597-2609.
20. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82: 60-70.
21. Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996) Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216: 133-145.
22. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B (2011) HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7: e1001256.
23. Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80: 4591-4600.
24. Silva MC, Schroer J, Shenk T (2005) Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc Natl Acad Sci USA 102: 2081-2086.
25. Silva MC, Yu QC, Enquist L, Shenk T (2003) Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J Virol 77: 10594-10605.
26. Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D, Co MS, Vasquez M, Britt WJ, Coelingh KL (1993) Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67: 489-496.
27. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89: 359-368.
28. Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn G (1997) Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods 63: 103-112.
29. Sinzger C, Mangin M, Weinstock C, Topp MS, Hebart H, Einsele H, Jahn G (2007) Effect of serum and CTL on focal growth of human cytomegalovirus. J Clin Virol 38: 112-119.
30. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ (1999) Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73: 7027-7030.
31. Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120: 3191-3208.
32. Tischer BK, von Einem J, Kaufer B, Osterrieder N (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40: 191-197.
33. Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994) Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201: 263-276.
34. Urban M, Britt W, Mach M (1992) The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66: 1303-1311.
35. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77(Pt 7): 1537-1547.
36. Utz U, Britt W, Vugler L, Mach M (1989) Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 63: 1995-2001.
37. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102: 18153-18158.
38. Wang D, Yu QC, Schroer J, Murphy E, Shenk T (2007) Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci USA 104: 20037-20042.
39. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC (2010) A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84: 2585-2596.
40. Wirtz N, Schader SI, Holtappels R, Simon CO, Lemmermann NA, Reddehase MJ, Podlech J (2008) Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med Microbiol Immunol 197: 151-158.
41. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180: 702-707.